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Introduction
Poor drug solubility remains one of the major challenges in drug discovery and development process as it leads to erratic absorption and poor oral bioavailability (Bellantone, 2014) . Poor solubility is also a key limiting factor in the development of volume-limited formulations such as ocular, intramuscular, pulmonary, and nasal dosage forms. According to Nernst-Brunner/Noyes-Whitney equation, low solubility implies slow dissolution rate, hence, compromising further drug bioavailability. Almost 60-70% of drugs in development are poorly soluble in water with almost 40% being practically insoluble (Bosselmann and Williams, 2012) . Over the years, different strategies have been developed to overcome poor solubility issues. This includes micronization and nanonization, particle engineering, amorphisation, solid dispersion, salts formation, the use of surfactant "micellization", cyclodextrins and polymeric complexations (Cavallari et al., 2005; Chen et al., 2011; Del Valle, 2004; Junghanns and Müller, 2008; Owen, 2013; Strickley, 2004) . Nevertheless, these strategies are not always able to satisfactorily improve the drug solubility and the combination of more than one strategy may be required. Therefore, the development of innovative solubility enhancing approaches is still needed to keep pace with the dramatically growing number of new drug candidates that are poorly soluble in water.
Known as the most abundant protein in plasma, albumin has been suggested as a non-toxic, biodegradable, highly soluble, and stable pharmaceutical excipient (Evans, 2002; Liu and Chen, 2016) . Albumin has several physiological functions such as maintaining plasma osmotic pressure and neutralising free radicals (Evans, 2002; Liu and Chen, 2016) . Most importantly, it plays the role of an "in-vivo solubilizing agent" allowing the solubilisation of a wide range of biomolecules and drugs in a hydrophilic medium, i.e. the plasma (Ghuman et al., 2005; Peters Jr, 1995) . The solubility enhancement properties of albumin are mainly due to its remarkable ability to form reversible binding complexes with ligands. This allows the bound molecule to flow in the blood at concentrations higher than that of its initial solubility (Ghuman et al., 2005; Urien et al., 2007) . Albumin has two main sites that bind the ligands mainly by hydrophobic and electrostatic interactions. Although the overall charge of albumin is negative at the physiological pH, the two principal binding sites are positively charged which promotes the binding of anionic molecules. Furthermore, albumin has several secondary binding sites increasing the number of bound molecules, e.g. up to seven fatty acid molecules (Evans, 2002) . Amongst substances showing the highest affinity to albumin, anionic molecules (weak acid) and hydrophobic molecules of medium size (100-600 Da); poorly soluble drugs (Peters Jr, 1995; Urien et al., 2007) . Interestingly, albumin molecule possesses numerous accessible free amino and carboxyl groups amenable to form highly soluble salts with acidic or basic drugs, respectively (Owen, 2013; Phelps and Putnam, 1960; Serajuddin, 2007) . Furthermore, the buffer capacity of albumin, although weak, may help in enhancing the solubility of drugs that are ionisable in the pH range of albumin solutions (pH 5.2-7) (Curvale, 2009) . Despite the exceptional capacity of albumin to physiologically dissolve poorly soluble drugs, no comprehensive study has yet explored the applicability of this unique property in-vitro. Though, few and partial data have been transiently mentioned in the literature (Devang et al., 2014; Kim et al., 2011; Li and Yao, 2009 ).
Bovine serum albumin (BSA) is chemically similar to human albumin and is widely used in pharmaceutical industry owing to its abundance, low cost, ease of purification, biocompatibility and biodegradability (Yu et al., 2014) .
The aim of this study is to comprehensively investigate the potential use of BSA as a solubility enhancer of IND (a model drug). IND is a member of acid class of non-steroidal anti-inflammatory drug that is described as poorly soluble and highly permeable (Class II) drug (El-Badry et al., 2009) .
It is has been reported that IND binds with high affinity to albumin molecule (Bogdan et al., 2008) and that its chemical structure is susceptible to form salt bridges with albumin amino groups (Trivedi et al., 1999) . Prepared by two different particle engineering techniques (freeze drying and spray drying), IND-BSA solid dispersions are characterised by different scanning electron microscopy (SEM), differential scanning calorimetry (DSC), and powder X-ray diffraction (XRD). IND aqueous solubility in the presence of increased amounts of BSA is evaluated. In addition, IND dissolution rates and release profiles are evaluated in-vitro under physiological conditions
Materials and Methods

Materials
BSA lyophilised powder was purchased from sigma-Aldrich (UK). IND was purchased from Acros organics (USA). Acetonitrile, sodium acetate, glacial acetic acid, orthophosphoric acid and all other materials and reagents used in the analytical methods were of analytical grade of purity and were all purchased from sigma-Aldrich (UK). 
Solid dispersions preparation
Spray-dried solid dispersion
For the spray dried formulations, resulting BSA-IND solution and suspension were spray-dried using a lab-scale nozzle-type spray dryer (Buchi, Switzerland) operated at feeding rate of 1 mL/min and an inlet and outlet temperatures of 120 °C and 50-60 °C, respectively.
The resulting solid dispersions were named as shown in table 1: IND and BSA powders, at similar molar ratios to the above, were mixed to produce dry physical mixtures (IND:BSA-PM) for comparison purposes.
Differential scanning calorimetry (DSC)
DSC analysis of IND, BSA, IND:BSA-PMs and the solid dispersions were performed using differential scanning calorimeter (Mettler Toledo, DSC822e, UK). Samples (2-5mg) were weighed and crimp-sealed in aluminium pans with the led pierced to ensure constant pressure. Analysis was carried out under nitrogen gas flow (20 mL/min) over a temperature range of 25 °C to 300 °C and at a heating rate of 10 °C/min. The obtained thermograms were analysed using STAReSW 10.00 software.
X-ray Diffractometry
IND, BSA, IND:BSA-PMs and the solid dispersions were also characterised by X-ray diffraction through Bruker diffractometer (Bruker AXS D8 Advance; Bruker Corporation, Billerica, MA, USA).
The diffractometer operated at room temperature and at 40 kV. The scanning diffraction angle (2θ) ranged from 2° to 45° with a step size of 0.1°. The data were collected and analysed using DIFFRAC plus XRD commander software (Bruker Corporation).
Scanning electron microscopy
Scanning electron microscopy (SEM) images of IND and BSA as raw powders, and the solid dispersion powders were obtained using Zeiss Evo50 electron microscope (Oxford instrument, UK).
Prior to imaging, the samples surfaces were sputter-coated with gold. The electron microscope was operated at an accelerating voltage of 30 kV under low-vacuum mode.
Aqueous solubility studies
The aqueous solubility of IND was carried out by adding excess amounts of IND (50 mg) to 1 mL BSA solutions of serial concentrations of (0, 0.3, 0.6, 0.9, 1.8 and 3.6 mM). In order to evaluate the solubility of IND formulated with BSA in the solid dispersions, calculated amounts of IND:BSA solid dispersions were added to 1 mL distilled water to obtain a range of BSA concentrations similar to the above mentioned. IND solubility was also evaluated in phosphate buffer (pH 7) in order to assess the solubility enhancement due to the pH effect of BSA solutions (pH 5.2-7, weak buffer capacity). The samples were shaken at 25 °C for 24 h until solubility equilibrium was reached. Samples were then centrifuged for 3 min at 10,000 rpm (RCF: 12.27 × 10 4 ) (Thermo Scientific, Germany) and the supernatants were filtered through 0.45 μm hydrophilic membrane filters (Rodisk, Gelman Sciences).
The filtrates were then collected and the drug concentration was determined by HPLC analysis. To evaluate the performance of BSA as solubility enhancer, the solubility enhancement factor was calculated as the ratio of IND apparent solubility in presence of BSA to its initial water solubility in the absence of BSA.
HPLC quantification of IND -Chromatographic conditions
Analysis was performed using PerkinElmer HPLC system (USA) which consisted of a degasser, a pump, an auto-sampler, and a UV detector. Chromatographic separation was achieved on a reversedphase analytical column (4.6×150mm, C18, 5μm, 130Å) (HyperClone TM ). The mobile phase consisted of 60 % acetonitrile and 40 % acetate buffer (0.02 M) and adjusted to pH 4 using orthophosphoric acid. The flow rate was 1.0 mL/min, the simple injection volume was 10 µl, and the UV-detector was set at 320 nm.
IND calibration standards were obtained in both the mobile phase and in BSA solution (0.03 mM, ~10 mg/L). In both media, the method was linear over a range of 2 µg/mL to 0.5 mg/mL, with correlation coefficients (r 2 ) in the range of (0.998 to 0.999). IND samples (BSA-free samples) were adequately diluted with the mobile phase and drug concentrations were calculated using the calibration curves prepared by mobile phase. For BSA-containing samples, supernatants were diluted with distilled water until meeting the BSA concentration in the calibration curves (i.e. 0.03 mM, ~10mg/L) and the drug concentrations were calculated according to the calibration curve prepared by BSA solution.
-Extraction procedure:
Briefly, filtered 0.2 mL of BSA-containing samples was placed in 1.5 mL Eppendorf tubes and 0.8 mL acetonitrile was added. Samples were vortex-mixed for 2 min, left for 30 min to complete BSA precipitation and centrifuged at 10,000 rpm (RCF: 12.27 × 10 4 ) (Thermo Scientific, Germany) for 5 min. The supernatants were filtrated through 0.45 μm Milipore filters and diluted 5 times with the mobile phase before being injected into the HPLC system.
Dissolution and release studies
In-vitro dissolution studies were performed using the USP Dissolution Apparatus 2-Paddle (CALEVA, UK). Dissolution studies of untreated IND powder, SD-sol, and FD-sol were conducted in 900 mL phosphate buffer, pH 7 at 37 ± 0.5 °C, using a stirring rate of 100 rpm and a dose equivalent to 20 mg IND. The powders were sprinkled over the dissolution medium and aliquots of 2 mL were withdrawn at 0, 5, 10, 15, 20, 30, 45 , and 60 min and filtered through 0.45μm Milipore filters before being analysed using UV spectrometer (JENWAY, UK) at 320 nm.
In-vitro drug release study was performed on the Franz diffusion cells (LOGAN Instruments Corp, USA) using cellulosic synthetic membrane (Cut-off 12 KD, Medicell Membrane Ltd, UK) that allows the diffusion of free drug only and prevents the transport of BSA. Synthetic membranes were soaked in distilled water for 24 h before being mounted between the two compartments of the Franz cell.
Receptor's compartment was filled with 12 mL phosphate buffer (pH 7) that was continuously homogenized using stirring magnetic bars and kept at 37 ± 0.5 °C. IND solution at (0.05% w/v) was prepared in distilled water containing (10% w/w) ethanol as co-solvent. Similarly, SD-sol and FD-sol solutions at equivalent concentrations of IND were prepared by dissolving appropriate amounts of solid dispersions in water. An aliquot of 2 mL of the mentioned IND solutions were placed in the donner compartment and covered with Parafilm to prevent the sample evaporation. Samples of 1 mL were collected after 0. 0.5, 1, 2, 3, 4, 5, and 6 h and replenished by fresh phosphate buffer. Samples were analysed using the UV spectrometry methods mentioned above.
Statistical analysis
Statistical significance was determined using the one-way analysis of variance (ANOVA) and Student's t-tests as appropriate. All experiments were performed in triplicate and values were expressed as the mean ± standard deviation. Values of P<0.05 were considered statistically significant. Fig. 1 shows the DSC thermograms of IND as a raw material and after formulating in BSA solid dispersion. Pure IND shows a sharp endothermic peak at 160 °C, assigned to its melting point (Heinz et al., 2007) . The same peak was also seen in IND:BSA-PM, indicating the crystalline state of the drug. However, the peak disappeared completely from all spray-dried and freeze-dried solid dispersions thermograms (Fig. 1) . Furthermore, the melting peak of IND was not shown at high IND:BSA ratios, i.e. SD-sus or FD-sus. Noteworthy, all resulting powders of solid dispersions were of yellow colour regardless IND:BSA molar ratios and the drying method.
Results
Solid dispersions characterisation
The solid state of IND in the BSA matrix was also examined using the XRD as shown in Fig. 2 .
The XRD pattern of pure BSA did not show any high-intensity diffraction peaks indicating its amorphous state. On the other hand, the XRD pattern of pure IND exhibits characteristic highintensity diffraction peaks corresponding to γ-IND crystal structure (Aceves-Hernandez et al.).
The same characteristic peaks were identified in the XRD pattern of IND:BSA-PM (Fig. 2) .
However, the XRD patterns of both spray dried and freeze dried IND:BSA solid dispersions show the complete disappearance of all the characteristic crystalline peaks of IND (Fig. 2) .
The surface morphology of IND, BSA and IND-BSA solid dispersions powders was examined using scanning electron microscopy (Fig. 3) . SEM micrographs of pure IND showed irregular shaped crystals whereas BSA SEM image revealed big plate-like chunks (Fig. 3a-b) . The SEM images of FDsol and FD-sus powder revealed ribbon-like and plate-like structures, respectively, without any evidence of crystallinity ( Fig. 3c-d) . SD-sol displayed rounded and smooth microparticles with an average size inferior to 2 µm and a single hole at their surface (Fig. 3e) . On the other hand, SD-sus powder displayed a smaller average size and slightly rougher surface with a complete absence of the holes (Fig. 3f) .
(e) FD-sus (scale bar 100µm) (e) SD-sol (scale bar 1µm), and (f) SD-sus (scale bar 1µm). (Samuel H. Yalkowsky, 2010) . However, IND solubility increased significantly to 5270 mg/L with an enhancement factor of 6500 fold in the presence of 3.6 mM BSA (24% w/v of BSA in water) (Fig. 4a) . Visually, the enhanced solubility of IND resulted in higher yellow colour intensity of the solutions; as the BSA concentration increased, more IND dissolved and the yellow colour of the resulting solution became more intense (Fig. 4c) .
Solubility studies
For better understanding of the solubility data, the phase solubility diagram was constructed by plotting the total molar concentration of dissolved IND against the total molar concentration of BSA (Fig. 4b) . The phase solubility diagram revealed a linear relationship with an "AL-type" and a slope of ~ 4, demonstrating that each albumin molecule dissolves four IND molecules (Higuchi, 1965) . The binding constant (K), which reflects the strength of the binding interaction, can be determined from the solubility diagram using the slope and the drug initial solubility (S0), i.e. drug solubility when no BSA is present (Loftsson et al., 2005) :
The BSA-IND binding constant estimated from the solubility diagram was ~ 6*10 5 mole -1 , which is also in accordance with previous reports (Khodarahmi et al., 2012; Trivedi et al., 1999) . IND solubility was also evaluated in a phosphate buffer (pH 7); although the IND solubility increased significantly to 472 mg/L (data not shown), this was significantly lower than the solubility enhancements obtained in BSA solutions.
-
IND-BSA solid dispersions
IND-BSA solid dispersions were prepared by both spray drying and freeze drying techniques using IND-BSA solution at (20:1 MR) which is 5 folds higher than the association stoichiometry (4:1) described in the previous section. Fig. 5a shows that IND solubility increased significantly after being formulated in SD-sol and FD-sol compared to that gained by the physical mixture (P<0.001).
Furthermore, FD-sol resulted in significantly higher solubility (P<0.05) compared to that of SD-sol (Fig. 5a ). IND solubility was improved ~20,000 fold by SD-sol and ~24,000 folds by FD-sol when BSA is added at 3.6 mM (the highest in this study) (Fig. 5) . The phase solubility diagrams revealed linear relationships with slopes of 12.5 and 14.2 in the case of SD-sol and FD-sol, respectively ( BSA molecules forming a colloidal suspension in water. It is worth to mention that the complete precipitation "separation" of BSA must be avoided, as this will reduce the interaction with the drug during the drying process and yield a solubility enhancement comparable to what was attained by physical mixture study (data not shown). Additionally, the fully precipitated BSA will hinder the spray drying process. Fig. 6a shows the dissolution profiles of IND (raw material), SD-sol and FD-sol, in phosphate buffer (pH 7) at 37 °C. The dissolution rate of IND was relatively slower than those of SD-sol and FD-sol with almost 70% dissolved after 1h (Fig. 6a) . On the other hand, formulating IND in BSA solid dispersions resulted in an immediate dissolution with almost 95% dissolved within the first 5 minutes.
Dissolution and release studies
In-vitro release of IND from BSA solid dispersions was evaluated across a semi-permeable membrane using vertical Franz diffusion cells under physiological conditions (phosphate buffer-pH 7 at 37 °C). 
Discussion
Particle-based solid dispersion is an established technology used to enhance drugs solubility.
Converting the drug into the amorphous state and the drug-carrier interactions are the instrumental factors in the design and performance of the relevant solid dispersion (Graeser et al., 2010; Huang and Dai, 2014) . Because of the higher Gibbs free energy of the amorphous form, the energy required to dissolve the drug from amorphous state is far less than that required for the equivalent amount from the crystalline state (Hancock and Zografi, 1997) . In addition, the hydrophilic surrounding matrix provided by the carrier (BSA) is expected to have a positive impact on the drug solubility and dissolution rate. In this study, two different particle engineering technologies were used to prepare IND:BSA solid dispersions; spray drying and freeze drying. The molecular proximity produced during the drying process is thought to promote additional interactions between BSA and IND, hence, improve the drug solubility further. The use of two different drying mechanisms might lead to different interactions between IND and BSA, hence, different solubility enhancement. In spray drying, the solvent removal takes place in milliseconds preventing phase separation between the drug and the carrier, while freeze dying involves the sample freezing followed by a very slow drying process taking place under low temperature and pressure.
The yellow colour of the obtained solid dispersions and the results of the SEM, DSC, and XRD ( Fig.   1-3 ) suggest the transformation of IND into the amorphous or/and molecular state within the BSA matrix (Cavallari et al., 2005) . A typical difference has been observed between the surface morphology of the microparticles spray dried from solution and those spray dried from suspension.
The presence of a single indentation in the surface of SD-sol microparticles could be explained by the formation of a skin-like outer layer on the droplet surface during the early stage of the drying process (Fig. 3) . This layer reduces the evaporating rate, hence, the cooling effect inside the droplet. As a result, a considerable rise in temperature and vapour pressure takes place inside the particle until the formed skin-like shell cracks open to allow vapour escaping. This results in a sudden under-pressure within the particle cavity causing the shell indentation (Walzel and Furuta, 2011) . In the case of SDsus microparticles, the presence of dispersed insoluble particles in the droplet renders the crust formed by drying process more diffusible (Fig. 3 ). This produces a permeable outer layer allowing a progressive evaporation of the liquid. As a result, the drying process, progressing from the outer shell, reduces the size of the droplet steadily and this leads to the absence of holes in smaller size microparticles (Walzel and Furuta, 2011 (Curry, 2002; Ghuman et al., 2005) . Several interactions may contribute to the IND:BSA binding process, including hydrophobic interactions, hydrophilic interactions and salt bridges formation (Bogdan et al., 2008; Zhang et al., 2012) . However, the major forces likely to be involved in IND-albumin binding are the hydrophilic forces for the first molecule of IND, followed by the formation of salt bridges between IND carboxylate groups and the positively charged residues of buried lysine in BSA molecules (Trivedi et al., 1999) . According to our results, each BSA molecule would provide three to four accessible lysine residues to interact with IND molecules and lead to the formation of highly soluble IND:BSA salt. Therefore, the salt bridges formation, IND-BSA binding, and to less extent IND ionisation are thought to be main reasons for the IND solubility enhancement observed in BSA solutions.
The preparation of BSA-IND solid dispersions helped to enhance the solubility of IND significantly compared to that of the physical mixture samples (Fig. 5) . Indeed, increasing IND:BSA molar ratio (to 20:1 and then to 100:1) and the extreme molecular proximity produced during the drying process are thought to promote the formation of additional salt bridges between the carboxylate groups of IND and the positively charged residues of BSA. Furthermore, the use of ethanol as co-solvent and the increased acidity caused by the co-dissolving of IND in BSA solution, might lead to conformational changes and then the unfolding of BSA molecule. Consequently, more buried lysine residues are exposed to the surface making them more accessible for interacting with indometacin (Edwards-Lévy et al., 1993) . Interestingly, the solid dispersions prepared by freeze drying offered significantly higher solubility of IND compared to those prepared by of spray drying technique. This might be attributed to the ultra-fast liquid nitrogen freezing followed by a soft and slow freeze drying process preserving the molecular distribution and interactions between IND and BSA molecules (Wanning et al., 2015) . Although having the same pH (data not shown), solid dispersions samples , 2009; ElShaer et al., 2011; Lin et al., 1991; Shibata et al., 2009 ).
The preparation of IND-BSA solid dispersions led to an effective enhancement in the dissolution rate of IND (Fig. 6a) . It is generally believed that the drug in amorphous state homogenously dispersed within a hydrophilic carrier enhances the dissolution rate effectively (Graeser et al., 2010) . Besides, the formation of salt bridges might also help protect the molecular state "solid solution" of IND in BSA matrix. As a result, the step of drug dissolution is bypassed resulting in the immediate dissolution reported in this study (Fig. 6a) (Fotaki et al., 2014) . After dissolution, the drug release from albumin complex is essential to allow an immediate absorption, hence, improved bioavailability.
The release experiment confirmed the ability of BSA to immediately release the bound IND. The concentration gradient and the osmotic pressure driving forces on both sides of the membrane seemed to be high enough to dissociate the IND molecules and render them immediately available for diffusion through the cellulosic membrane mounted to Franz diffusion cell (Fig. 6b) . This reflects the weakness the intermolecular forces associating IND to BSA molecules.
Conclusion
In this study, the use of BSA as a solubility enhancer of IND, a model drug, was demonstrated. In a physical mixture of both, the solubility of IND was found to be dependent on the concentration of BSA. Particle engineering techniques such as spray drying and freeze drying, used to prepare solid dispersions of IND in BSA, were of great importance in producing significant enhancement in drug solubility compared to that of aforementioned physical mixture. Solid dispersions prepared from IND:BSA suspensions (100:1 MR) showed superior drug solubility compared to that made from IND:BSA solutions (20:1MR). Furthermore, freeze drying technique was found to yield solid dispersions having significantly higher solubility than that of the corresponding ones prepared by spray drying. Particle engineering techniques were found to transform the drug into an amorphous state and the drug-albumin interactions were believed to include hydrophobic interactions, hydrophilic interactions and salt bridges formation. In-vitro dissolution studies showed a significant increase in the dissolution rate of IND from solid dispersions compared to that of the free drug, and an immediate release of IND from BSA solid dispersions was reported. Overall, the results demonstrated the importance of particle engineering technology to prepare albumin-drug solid dispersions as a method of enhancing the solubility and the dissolution of poorly water soluble drugs. Future work may include investigating the use of albumin solid dispersion to enhance the solubility of poorly water soluble drugs that are lipid soluble or none-ionised. Additionally, stability upon storage and cost effectiveness need to be studied before albumin can be used to improve drugs solubility.
